Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells 7,031 Shares of Company Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Jessica Newcomb sold 7,031 shares of the firm’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $22.42, for a total transaction of $157,635.02. Following the sale, the insider directly owned 52,090 shares in the company, valued at approximately $1,167,857.80. The trade was a 11.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Jessica Newcomb also recently made the following trade(s):

• On Tuesday, September 22nd, Jessica Newcomb sold 8,200 shares of Tango Therapeutics stock. The stock was sold at an average price of $24.22, for a total transaction of $198,604.00.

Tango Therapeutics Stock Up 0.0%

Tango Therapeutics stock traded up $0.01 during midday trading on Wednesday, reaching $23.18. 2,464,255 shares of the company traded hands, compared to its average volume of 4,639,952. Tango Therapeutics, Inc. has a 12 month low of $7.37 and a 12 month high of $34.39. The business has a 50 day moving average of $23.50 and a two-hundred day moving average of $22.39.

Tango Therapeutics (NASDAQ:TNGX) last posted its earnings results on Tuesday, August 11th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.05). Research analysts anticipate that Tango Therapeutics, Inc. will post -1.41 EPS for the current year.

Hedge Funds Weigh In On Tango Therapeutics

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in Tango Therapeutics during the second quarter valued at $388,826,000. TRV GP IV LLC purchased a new stake in Tango Therapeutics in the second quarter worth about $120,181,383,000. Jupiter Topco LLC purchased a new stake in Tango Therapeutics in the second quarter worth about $157,989,000. Seven Fleet Capital Management LP raised its stake in shares of Tango Therapeutics by 302.2% in the second quarter. Seven Fleet Capital Management LP now owns 3,228,144 shares of the company’s stock worth $95,661,000 after buying an additional 2,425,484 shares during the period. Finally, Jefferies Financial Group Inc. bought a new position in shares of Tango Therapeutics in the second quarter worth about $62,849,000. 78.99% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on TNGX. HC Wainwright reaffirmed a “buy” rating and issued a $68.00 price objective on shares of Tango Therapeutics in a report on Thursday, October 29th. Stifel Nicolaus set a $55.00 target price on Tango Therapeutics in a report on Friday, October 23rd. William Blair assumed coverage on Tango Therapeutics in a research report on Friday, October 16th. They issued an “outperform” rating on the stock. Weiss Ratings upgraded Tango Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, Guggenheim upped their price target on shares of Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Tango Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.62.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines for cancer. The company uses functional genomics and genetic screening to identify vulnerabilities in tumor cells, including dependencies created by tumor-suppressor gene loss, and to develop targeted therapies designed to selectively attack cancer cells.

Tango’s pipeline includes small-molecule programs for genetically defined solid tumors. Its lead program, TNG462, is an MTA-cooperative PRMT5 inhibitor being developed for cancers with MTAP gene deletions.